Oxford Cancer Biomarkers (OCB) have made another key appointment. The company has hired a Medical Science Liaison Manager to strengthen operations and support continued growth. This follows the accelerating adoption of ToxNav® a comprehensive genetic blood test that identifies cancer patients at high risk of severe and potentially fatal side-effects when treated with 5FU or capecitabine containing chemotherapy regimens.
Calum Johnstone has joined OCB as the Medical Science Liaison Manager, aiming to enhance OCB’s services to the medical profession. Calum’s role will facilitate communication between key stakeholders in the NHS and private hospital settings, supporting the introduction of ToxNav®. Calum brings a wealth of knowledge and expertise to OCB, having recently moved to the UK from New Zealand after spending 4.5 years in the pharmaceutical industry where he gained experience in sales, account management, medical science, brand management and multiple product launches.
Calum commented “I’m thrilled to have joined the Oxford Cancer Biomarkers team at this exciting time as we introduce and grow our flagship product, ToxNav® – DPYD testing to assess the risk of fluoropyrimidine related toxicity and guide physician management using regimens containing 5FU or capecitabine.”
Further information contact:
Paul Blackburn, Certatim Consulting on behalf of Oxford Cancer Biomarkers
01243 649002 firstname.lastname@example.org